公开(公告)号：US20250161271A1

公开(公告)日：2025-05-22

申请号：US18838591

申请日：2023-02-15

Applicant: KANAPH THERAPEUTICS INC. ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Donggeon KIM ,  Yeri LEE ,  Sang Kyun LIM ,  Young Sook SHIN ,  Soo Bong HAN ,  Chang Soo YUN ,  Hyuk LEE ,  Hyun Jin KIM ,  Joo Youn LEE ,  Si Kwang SEONG ,  Taeyoung YOON ,  Youngrae LEE

IPC: A61K31/407 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4155 ,  A61K31/4436 ,  A61K31/4535 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising a novel compound that inhibits the activity of prostaglandin E2 receptor and an anticancer agent as active ingredients. The novel compound of the present invention inhibited the activity of prostaglandin E2 receptor and inhibited tumor growth in colorectal cancer and lung cancer tumor models. In addition, it was found that when administered in combination with other anticancer agents such as a chemotherapeutic agent and/or an immune checkpoint inhibitor, a synergistic effect was exhibited in anticancer activity. Therefore, a pharmaceutical composition for treating cancer, comprising the novel compound and an anticancer agent as active ingredients may be effectively used for the prevention and treatment of cancer.

公开(公告)号：US20250090491A1

公开(公告)日：2025-03-20

申请号：US18797480

申请日：2024-08-07

Applicant: Novartis AG ,  Katholieke Universiteit Leuven ,  Korea Research Institute of Chemical Technology

Inventor： Johan NEYTS ,  Daniel POON ,  Keith Bruce PFISTER ,  Young-Sik JUNG ,  Soo Bong HAN ,  Yashwardhan R. MALPANI ,  Prashant CHAKRASALI ,  Sang-Ho LEE ,  Chong-Kyo LEE ,  Chonsaeng KIM ,  Jin Soo SHIN ,  Hae Soo KIM

IPC: A61K31/343 ,  A61P31/14 ,  C07D307/93

Abstract: This disclosure provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.

公开(公告)号：US20230365582A1

公开(公告)日：2023-11-16

申请号：US18042352

申请日：2021-08-20

Applicant: KANAPH THERAPEUTICS INC. ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Young Sook SHIN ,  Sang Kyun LIM ,  Yeri LEE ,  Donggeon KIM ,  Soo Bong HAN ,  Chang Soo YUN ,  Hyun Jin KIM ,  Joo Youn LEE ,  Hyuk LEE ,  Sikwang SEONG

IPC: C07D495/04 ,  C07D333/24 ,  C07D333/38 ,  C07D409/10 ,  C07D409/06

CPC classification number: C07D495/04 ,  C07D333/24 ,  C07D333/38 ,  C07D409/10 ,  C07D409/06

Abstract: The present application relates to a novel compound having inhibitory activity on prostaglandin E2 receptor and uses thereof, and provides a compound represented by formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a method of using the same.

公开(公告)号：US20250009742A1

公开(公告)日：2025-01-09

申请号：US18699156

申请日：2022-10-12

Applicant: AM SCIENCES INC ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Nakcheol JEONG ,  Misun LEE ,  Heewoo SIM ,  Myungjin KIM ,  Jung-Hee KIM ,  Soo Bong HAN ,  Young Sik JUNG ,  Hye jin KIM ,  Chang Soo YUN ,  Heeyeong CHO ,  Mee Hyein KIM ,  Joo Youn LEE

IPC: A61K31/501 ,  A61K31/4155 ,  A61K31/4162 ,  A61K31/422 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61P31/20 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D471/04 ,  C07D491/052 ,  C07D491/056 ,  C07D495/04

Abstract: The present invention relates to a series of novel pyrazolylmethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.

公开(公告)号：US20150336920A1

公开(公告)日：2015-11-26

申请号：US14651656

申请日：2013-12-16

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KATHOLIEKE UNIVERSITEIT LEUVEN K.U.LEUVEN R & D

Inventor： Young Sik JUNG ,  Soo Bong HAN ,  Chong-Kyo LEE ,  Hae Soo KIM ,  Jin Soo SHIN ,  Neyts JOHAN ,  Jan Thibaut HENDRIK ,  Yashwardhan Radhamohan MALPANI

IPC: C07D307/93 ,  C07D417/12 ,  C07D407/12 ,  C07D405/12 ,  C07D409/12

CPC classification number: C07D417/12 ,  C07D307/93 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12

Abstract: The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

Abstract translation: 本发明涉及一种新型化合物，其药学上可接受的盐或其旋光异构体及其制备方法，以及用于预防或治疗含有作为活性成分的病毒性疾病的药物组合物。 本发明的新型化合物不仅细胞毒性低，而且对柯萨奇病毒，肠道病毒，回波病毒，脊髓灰质炎病毒和鼻病毒等小RNA病毒具有优异的抗病毒活性，因此可有效地用作预防或治疗病毒的药物组合物 疾病如婴儿瘫痪，急性出血性结膜炎，病毒性脑膜炎，手足口病，囊泡病，甲型肝炎，肌炎，心肌炎，胰腺炎，糖尿病，流行性肌痛，脑炎，感冒，疱疹，口蹄疫 疾病，哮喘，慢性阻塞性肺病，肺炎，鼻窦感染或中耳炎。

公开(公告)号：US20230248734A1

公开(公告)日：2023-08-10

申请号：US18001333

申请日：2021-06-08

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Soo Bong HAN ,  Jin Soo SHIN ,  Mee Hyein KIM ,  Eunhye JUNG ,  Ye Jin JANG ,  Hyuk LEE ,  Myoungkyu LEE ,  Dongsu KIM ,  Chang Soo YUN ,  Young Sik JUNG

IPC: A61K31/53 ,  A61K31/495 ,  A61K31/138 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4453 ,  A61K31/40 ,  A61K31/445 ,  A61P31/14 ,  G01N33/50

CPC classification number: A61K31/53 ,  A61K31/495 ,  A61K31/138 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4453 ,  A61K31/40 ,  A61K31/445 ,  A61P31/14 ,  G01N33/5091

Abstract: The present invention relates to the development of a composition for the treatment of novel SARS-coronavirus-2 infection. The drug efficacy was evaluated through CPE (Cytopathic Effect)-based assay method that measures how long the cells survive by infecting SARS-CoV-2 after receiving a drug library previously approved as a treatment for a specific disease from the Korea Chemical Bank and treating Vero cells with the drug, and an image-based assay that measures how much virus is reduced in infected cells. Through this, 16 kinds of drugs effective in the treatment of SARS-CoV-2 were re-positioned.

公开(公告)号：US20160297789A1

公开(公告)日：2016-10-13

申请号：US15189771

申请日：2016-06-22

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D

Inventor： Young Sik JUNG ,  Chong Kgo LEE ,  Hae Soo KIM ,  Hee Chun JEONG ,  Pil Ho KIM ,  Soo Bong HAN ,  Jin Soo SHIN ,  Johan NEYTS ,  Hendrik Jan THIBAUT

IPC: C07D307/93 ,  C07D491/048 ,  C07D405/04 ,  C07D409/12 ,  C07D405/12 ,  C07F9/655 ,  C07D417/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  C07D209/94 ,  C07C233/32 ,  C07D407/12

CPC classification number: C07D307/93 ,  C07C233/32 ,  C07D209/94 ,  C07D405/04 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07F9/65517

Abstract: Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Abstract translation: 公开了新颖的茚酮衍生物，其药学上可接受的盐或对映体，其制备方法和用于预防或治疗病毒性疾病的药物组合物，其包含其作为活性成分。 茚酮衍生物对包括柯萨奇，肠反应，脊髓灰质炎和鼻病毒的小核糖核酸病毒具有优异的抑制活性，并且具有低的细胞毒性，因此它们可用作药物组合物的活性成分，用于预防或 治疗包括脊髓灰质炎，麻痹，急性出血性结膜炎，病毒性脑膜炎，手足口病，囊泡病，甲型肝炎，肌炎，心肌炎，胰腺炎，糖尿病，流行性肌痛，脑炎，感冒，呼吸窘迫综合征， 口腔疾病，哮喘，慢性阻塞性肺病，肺炎，鼻窦炎或中耳炎。